Piramal Enterprises receives nod from USFDA for anti-diabetes ...

Piramal Enterprises is currently trading at Rs. 577.50, up by 4.75 points or 0.83% from its previous closing of Rs. 572.75 on the BSE. The scrip opened at Rs. 570.00 and has touched a high and low of Rs. 580.00 and Rs. 570.00 respectively. So far ...

Piramal Enterprises (PEL) has inked pact with Tata Memorial Centre (TMC) in order to enable development of tools for better understanding of the disease and to predict responses to various treatments for cancer patients. With this initiative, both ...

Piramal Enterprises is currently trading at Rs 596.25, up by 1.50 points or 0.25% from its previous closing of Rs 594.75 on the BSE. The scrip opened at Rs 595.45 and has touched a high and low of Rs 598.00 and Rs 595.45 respectively. The BSE group ...

ns, classifications, efficiency norms — India Inc is no stranger to bruising battles over them. But rarely ever has a government formed an inter-ministerial group (IMG) to settle what is essentially a business battle: Should quadricycles be ...

The clinical trial industry in India is currently facing a challenging time and witnessing a downward trend as investors are looking to shift their focus to other liberal destinations like China, Turkey and Malaysia, says Dr C Raghu, director of ...

Anhal will also handle the operations of ZeeQ, the edutainment channel from Zee Learn. Zee Learn has promoted Navneet Anhal, erstwhile chief operating officer, as its chief executive officer. As a part of his mandate, Anhal will also handle the ...

The Supreme Court recently rejected Swiss pharma giant Novartis's plea to extend its patent for a life-saving drug imatinib mesylate, sold under the brand name Glivec. The court did not find the improvement on the existent drug significant enough.

Credit rating agency, CARE has reaffirmed D rating to Themis Medicare's long term bank facilities worth Rs 13.10 crore. The rating agency has also reaffirmed D rating to the company's short term bank facilities. The company has received the said ...

Themis Medicare (Themis) has entered into a License and Supply Agreement with Novartis India (Novartis) on March 26, 2013. As per agreement, Themis has agreed to manufacture and supply Diclofenac topical gel formulated using unique TPM transdermal ...